Multiple successful desensitizations to brentuximab vedotin: A case report and literature review

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 4, 2014, Pages 465-471

  DeVita, Michael D ^a   Evens, Andrew M ^b   Rosen, Steven T ^a   Greenberger, Paul A ^a   Petrich, Adam M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIEMETIC AGENT; BENDAMUSTINE; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FAMOTIDINE; FEXOFENADINE; FLUCONAZOLE; GEMCITABINE; HYDROCORTISONE; HYDROXYZINE; IBUPROFEN; LORAZEPAM; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MONTELUKAST; ONDANSETRON; PARACETAMOL; PREDNISONE; ROMIDEPSIN; VINCRISTINE; ANTIBODY CONJUGATE; CAC10-VCMMAE;

ADULT; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CASE REPORT; CERVICAL LYMPHADENOPATHY; COMPUTER ASSISTED TOMOGRAPHY; CONVULSION; DESENSITIZATION; DRUG DOSE TITRATION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FAINTNESS; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INTENSIVE CARE UNIT; LARGE CELL LYMPHOMA; LIVER INJURY; LOW DRUG DOSE; LYMPHADENOPATHY; MAXILLARY SINUS; MEDICAL HISTORY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTIMODAL CHEMOTHERAPY; MULTIPLE CYCLE TREATMENT; MYOSITIS; NAUSEA; OBESITY; PANCYTOPENIA; PATIENT MONITORING; PERIORBITAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PRURITUS; RASH; SKIN BIOPSY; SKIN DEFECT; STEM CELL MOBILIZATION; STEROID THERAPY; T CELL LYMPHOMA; TACHYCARDIA; URTICARIA; IMMUNOLOGY; LYMPHOMA, LARGE-CELL, ANAPLASTIC; PROCEDURES;

ADULT; DESENSITIZATION, IMMUNOLOGIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, LARGE-CELL, ANAPLASTIC;

EID: 84900404331     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0052     Document Type: Article

References (25)

1. Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008;122:574-580.
2. Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-276. (Pubitemid 43053551)
3. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-5504.
4. Swerdlow SH, International Agency for Research on Cancer, World Health Organization. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
5. Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-3425.
6. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999;93:3913-3921. (Pubitemid 29249840)
7. Sibon D, Fournier M, Briere J, et al. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials. J Clin Oncol 2012;30:3939-3946.
8. Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2009;161:121-127.
9. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653-3661. (Pubitemid 30412833)
10. Jacobsen E. Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist 2006;11:831-840. (Pubitemid 44157571)
11. Kewalramani T, Zelenetz AD, Teruya-Feldstein J, et al. Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. Br J Haematol 2006;134:202-207. (Pubitemid 43893913)
12. Rodriguez J, Munsell M, Yazji S, et al. Impact of high-dose chemotherapy on peripheral T-cell lymphomas. J Clin Oncol 2001;19:3766-3770. (Pubitemid 32844790)
13. Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999;17:423-429. (Pubitemid 29022421)
14. de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-5849.
15. Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nature Biotechnol 2003;21:778-784. (Pubitemid 36791396)
16. Sutherland MS, Sanderson RJ, Gordon KA, et al. Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates. J Biol Chem 2006;281:10540- 10547. (Pubitemid 43864594)
17. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003;102:1458-1465. (Pubitemid 36988057)
18. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190-2196.
19. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821.
20. Baxley AA, Kumm DE, Bishop CB, et al. Severe infusion reactions to brentuximab vedotin in two patients with Hodgkin lymphoma previously treated with allogeneic stem cell transplantation. J Oncol Pharm Pract 2013;19:279-283.
21. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007;12:601-609.
22. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803-843. (Pubitemid 36432084)
23. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999;17:791-795. (Pubitemid 29109307)
24. DeNardo GL, Bradt BM, Mirick GR, DeNardo S. Human antiglobulin response to foreign antibodies: therapeutic benefit? Cancer Immunol Immunother 2003;52:309-316. (Pubitemid 36581907)
25. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol 1994;15:42-52. (Pubitemid 24005093)